Therapeutic Effect of Botulinum Toxin a on Children with Spastic Cerebral Palsy: Meta-analysis

Abstract

To systematically evaluate the clinical effect of botulinum toxin A (BXT-A) on children with spastic cerebral palsy. All clinical randomized controlled trials (RCTs) of BXT-A in children with spastic cerebral palsy were collected from the database establishment to April 20, 2021. Meta-analysis was performed on the extracted data using Review Manager 5.4 and R 4.0 software. A total of 21 studies met the inclusion criteria, including 1357 cases of spastic cerebral palsy and 704 cases in the BTX-A+ rehabilitation group. Meta-analysis results showed that: MAS score [MD=-0.83, 95%CI (-0.86, -0.80), Z=51.03, P<0.05] and GMFM-88 score [MD=5.50, 95%CI (4.40, 6.59), Z=9.85, P<0.05] in BTX-A+ rehabilitation treatment group, GMFM-D score [MD=8.51, 95%CI (5.24, 11.78), Z=5.09, P<0.05], GMFM-E score [MD=8.44, 95%CI (5.16, 11.72), Z=5.04, P<0.05], CSS score [MD=-1.86, 95%CI (-3.07, -0.66), Z=3.03, P<0.05], PRS score [MD=0.85, 95%CI (0.26, 1.44), Z=2.83, P<0.05] were better than the rehabilitation treatment group in these aspects, and the diversity between the two groups was statistically (P<0.05). BTX-A can effectively enhance motor function, and is an effective method for the treatment of children with spastic cerebral palsy.